HEALTH

Doctor recommendations influence cold-flu-allergy OTC purchase

BY Michael Johnsen

Product consideration at the shelf level remains a driving force behind purchase decisions. According to an online survey of more than 500 AccentHealth viewers conducted in August, 34% of respondents indicated that in-store browsing influences their OTC purchase. However, 40% of respondents indicated that OTCs purchased to treat cold, flu and allergy were the result of a doctor recommendation. To see more Patient Views, click here

Patient Views is an exclusive consumer insights feature that appears regularly in DSN magazine, as well as the daily e-newsletter DSN A.M. If you could ask more than 6,500 patients anything at all, what would it be? Send your questions to [email protected].

Source: AccentHealth. To view the demographic breakdown of participants, click here.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

World Self-Medication Industry names president of Bayer HealthCare’s Global Consumer Care division chair-elect

BY Michael Johnsen

LEVERKUSEN, Germany — The board of directors of the World Self-Medication Industry on Wednesday named as its chair-elect Erica Mann, member of the Bayer HealthCare executive committee and president of Bayer HealthCare’s Global Consumer Care division. Mann will succeed current chair Zhenyu Guo, CEO, Dihon Pharmaceutical at the completion of his term in June 2014.

“I am honored to be appointed the incoming WSMI Chair, particularly at a time when consumer self-medication trends have never been stronger, and broadening of nonprescription medicine availability is now under consideration in many parts of the world," Mann said. "In this time of tightening public health budgets, self-medication can empower consumers to take a greater role in the management of their own health care while reducing unnecessary physician and hospital visits,” she added. “Given today’s evolving regulatory and commercial environments, there is a growing sense that our industry must strengthen its engagement in policy issues on a global level, taking a consumer-centric approach across countries and regions.”

Mann has been a member of the Bayer HealthCare executive committee and responsible for the Consumer Care division since mid-March 2011. She began her career in the pharmaceutical industry in 1982 at Eli Lilly & Company in South Africa as a medical representative. This was followed by positions in marketing at Johnson & Johnson and Lederle Laboratories. In 1992 she was appointed as head of the Lederle Pharmaceutical business in South Africa and in 1994, Mann transferred to Wyeth as managing director for South Africa and sub-equatorial Africa. She then held positions of increasing responsibility at the company through 2009. In 2003, she was appointed managing director of the Wyeth Australia and New Zealand affiliate, where she introduced a range of significant medicines and nutritionals. In April 2009 she assumed the role of SVP  for Wyeth’s Global Nutritional Business and in October 2009 she moved to the United States to join Pfizer upon its acquisition of Wyeth where she was most recently president and general manager for the nutrition division and a member of Pfizer’s senior management team.

In addition to currently serving as a WSMI board member, Mann has held executive positions in several industry organizations, including the South African Pharmaceutical Manufacturers’ Association and Medicines Australia, as well as the International Association of Infant Food Manufacturers.

The WSMI is a federation of around 50 member associations representing manufacturers and distributors of non-prescription medicines and other self-care products on all continents. WSMI aims to create and maintain an international environment intended to improve the opportunities for people to manage their own health through the responsible use of safe and effective self-medication products. 


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
HEALTH

Prestige Brands named to Fortune’s list of 100 fastest-growing companies

BY Michael Johnsen

TARRYTOWN, N.Y. — Fortune has named Prestige Brands as one of its 100 fastest-growing companies, Prestige announced Tuesday. Listed as No. 60, Prestige represents the only manufacturer of brand name over-the-counter healthcare products on the list. 

“Our strategy for creating shareholder value has three prongs which work in tandem — invest in and grow our core over-the-counter healthcare brands, harness our financial profile and industry-leading free cash flow to pay down debt and build M&A capacity, and remain aggressive and disciplined in the M&A market,” stated Matthew Mannelly, CEO. “The successful execution of this strategy worked to create the results for which we are recognized on this important Fortune list.” 

The Fortune list measures companies by growth in revenue, profit and stock price over the past three years. Prestige’s strong financial performance included a 30% revenue growth, 30% adjusted EPS growth and 60% total return for the three-year period.


Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?